Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

NCT04341116 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

149

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronavirus Disease 2019 COVID-19

Interventions

DRUG: TJ003234
DRUG: Placebo

Sponsor

I-Mab Biopharma US Limited